Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
2009 · European Journal of Cancer · 365 citations
https://doi.org/10.1016/j.ejca.2009.02.011
S
Samuel E. DePrimo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
6.7K
Citations
29
h-index
35
i10-index
Samuel E. DePrimo is an academic researcher from Poseida Therapeutics (United States). The author has contributed to research in topics: Gastrointestinal Tumor Research and Treatment & Renal cell carcinoma treatment & Colorectal Cancer Treatments and Studies. The author has an h-index of 29, co-authored 46 publications.
Papers by this author
worksTranscriptional programs activated by exposure of human prostate cancer cells to androgen
2002 · Genome biology · 193 citations
https://doi.org/10.1186/gb-2002-3-7-research0032
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
2013 · Cancer Chemotherapy and Pharmacology · 59 citations
https://doi.org/10.1007/s00280-013-2333-4
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
2011 · Journal of Translational Medicine · 25 citations
https://doi.org/10.1186/1479-5876-9-120
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
2012 · Journal of Translational Medicine · 10 citations
https://doi.org/10.1186/1479-5876-10-165
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat